ERBB2 and breast carcinoma: Notably, a slightly higher percentage of patients with a high AL presented with HR negative/ERBB2 negative breast cancer (345 patients [15.7%] vs 301 patients [13.3%]) or HR positive/ERBB2 negative cancer (420 patients [19.1%] vs 398 patients [17.6%]) than patients with low AL.